of new long acting depot testosterone preparations (4-6), but their effects on human spermatogenesis have yet to be determined (7). To fill this gap in knowledge, we have studied the effects of an existing depot testosterone formulation, testosterone pellet implants that have nearideal depot steady state release properties (8, 9) , to determine the likely effects of a depot testosterone formulation either alone or in conjunction with a second gonadotropin-suppressing agent (10). In a previous study we established that use of a depot testosterone formulation allowed achievement of major (>50%) reductions in the delivered testosterone dose while maintaining equally effective suppression of spermatogenesis with similar or fewer metabolic side-effects (11). The testosterone dose used in that first study of testosterone implants (1200 mg; testosterone delivery, 9 mg/ day) was arbitrarily selected toward the upper range of doses used conventionally for androgen replacement therapy, which also correspond with the normal endogenous daily production rate (3-10 mg testosterone/day). Second generation hormonal regimens for male contraception under consideration include androgen alone or in combination with second gonadotropin-suppressing agents, such as progestins or GnRH antagonists (10). As a testosterone depot is the basis of all such hormonal regimens, the properties of long acting depot testosterone formulations alone or in concert with second agents are, therefore, critical to future strategies for the development of hormonal male contraception. This study then aimed to examine lower testosterone doses spanning the range of normal testosterone production rates to determine in healthy men 1) the minimum testosterone dose still consistent with effective spermatogenic suppression and 2) how effectively a depot progestin would be in augmenting the highest suboptimal testosterone dose.
Subjects and Methods

Study design and procedures
The study aimed to 1) undertake a downward dose range to determine the minimum testosterone dose that could maintain effective spermatogenic suppression and 2) to determine the effects of a depot progestin when it was added to the first suboptimally suppressive testosterone dose. The study was undertaken in two stages. First, 20 men were randomized into two groups to receive either two or four 200-mg testosterone implants (total dose, 400 or 800 mg; daily release rate, 3.0 or 6.0 mg / day) (8, 9 
Subjects Results
The men entering this study did not differ between groups (n = 10) in age, height, weight, body surface area, body mass index, or testis size (Table 1) and were similar to our ongoing control group (12) of healthy men screened as potential sperm donors (n = 509; data not shown). Implantation of testosterone pellets was well tolerated.
There were 2 extrusion episodes among the 30 procedures in this study, both involving a single pellet extruding from men in the combined treatment group and occurring at weeks 11 and 14 after implantation.
There were no discontinuations or serious adverse effects reported by participants or any changes in mood or behavior observed by study personnel. Mild acne was reported by 3 of 10 men receiving 800 mg testosterone and 1 of 10 receiving 800 mg testosterone plus DMPA. None required any specific treatment for acne. Increased libido at the start of the study was reported by 5 of 10 men in the 800 mg testosterone plus DMPA group and by 1 of 10 men after 800 mg testosterone alone, but only 1 regarded this as troublesome. One man receiving 800 mg testosterone alone felt that he was transiently more aggressive. There were no adverse effects reported in men receiving 400 mg testosterone. All subjects completed the study, and 412 of 420 (98%) semen samples required for primary endpoint evaluation were obtained. There were no differences in baseline sperm output (overall median, 80 mol/L*mL) among men entering the three groups ( Table 2 ). The lowest testosterone dose (two implants, 400 mg) had a minimal effect on sperm output, and none became azoospermic (Fig. 1) .
The higher testosterone dose (four implants, 800 mg) alone significantly suppressed sperm output, but significant between-subject heterogeneity was evident, with four men ren- the study (Fig. 2 ). There were, however, significant differences between treatments in the time course of blood total and free testosterone (treatment X time interactions, P < 0.001). Total and free testosterone increased modestly after 800 mg testosterone alone, but both decreased after 800 mg testosterone plus 300 mg DMPA, whereas 400 mg testosterone had no consistent effect on testosterone concentrations over time.
I
: Y Epitestosterone concentrations were significantly reduced by all three treatments in a dose-dependent fashion (Fig. 2) Among men receiving 800 mg testosterone alone, the only significant difference between those who did (n = 4) and those who did not (n = 6) become azoospermic was a lower baseline urea concentration (4.3 2 0.5 us. 6.0 ? 0.5; P = 0.046), but not in any other baseline anthropometric, seminal, hormonal, or biochemical variables. Men who became azoospermic had significantly lower overall total and free testosterone concentrations, but there was no difference in epitestosterone concentrations or time course of total or free testosterone, epitestosterone, LH, or FSH concentrations according to for men became azoospermic DS. those who did not (azoospermia X time interaction, P > 0.05). The combination of 800 mg testosterone with 300 mg DMPA caused a striking fall in sperm output, with 9 of 10 reaching azoospermia and all reaching severe oligozoospermia (~3 mol/ L/mL).
In the two groups receiving 800 mg testosterone, the nadir of sperm output was reached at 2-3 months, with marked suppression lasting for -3 months followed after the 4th month by a gradual return in sperm output toward normal and reaching baseline levels in the 10th month but without overshoot. Essentially identical patterns were observed whether expressed as concentrations or total output of motile or all sperm. The study provided a power of more than 90% to reject each of the following hypotheses that 1) 800 mg testosterone alone would induce azoospermia uniformly (loo%), and 2) the addition of DMPA had no effect on induction of azoospermia. T), 3 (800 mg T), and 20 (800 mg T plus 300 mg DMPA) of the blood samples taken at weeks 4 (5 samples), 8 (7 samples), 12 (6 samples), 16 (4 samples), and 20 (1 sample). There was no evidence of LH rebound during recovery. Similar findings were confirmed using the Delfia LH assay (data not shown). Plasma FSH concentrations were significantly reduced in the first month in both groups receiving 800 mg testosterone, but not in the 400 mg testosterone group (Fig. 3) . Both the extent and duration of inhibition as well as the rate of recovery were dose dependent, remaining suppressed for 3 months by testosterone alone and for 4 months with the addition of DMPA treatment (Table 3) . Undetectable levels were observed in 0 (400 mg testosterone), 3 (800 mg testosterone), and 2 (800 mg testosterone plus 300 mg DMPA) of the blood samples taken at weeks 8 (one sample) and 12 (four samples). There was no evidence of FSH rebound during recovery. Similar findings were confirmed using the Delfia FSH assay (data not shown).
Inhibin concentrations were decreased in a dose-dependent manner (73 ? lo%, 51 + 9%, and 27 ? 4% of baseline inhibin levels), with a nadir at 3 months and subsequent recovery (Fig. 4) . SHBG concentrations were significantly reduced by DMPA administration, but not by either testosterone dose (Fig. 4) .
To determine whether the effects of DMPA on testosterone could be explained by the reduced SHBG levels, the greater inhibition of LH levels, or other effects, we examined the effects of DMPA on total testosterone concentrations using either concurrent SHBG or LH levels as covariates. Adjustment for either covariate, however, had little influence on the DMPA effect on the time course of testosterone, which remained highly significant (treatment x time interactions, P < 0.0001).
Metabolic effects of testosterone
There were no significant effects of either testosterone dose or DMPA on prostate-specific antigen (Fig. 4) by more than 50%, blood testosterone levels were reduced to remain within the physiological range, and some, but not all, metabolic effects of testosterone were reduced (11). The testosterone dose used in that first study of testosterone implants (1200 mg) was arbitrarily selected toward the upper range of doses used conventionally for androgen replacement therapy (9), and its daily delivery rate of testosterone (9 mg/day) also corresponds with the upper limits of normal endogenous testosterone daily production (3-10 mg/day).
These results prompted the present downward dose-ranging study to determine the minimum testosterone dose that could maintain optimal spermatogenic suppression.
This study now identifies the limits of a testosterone depot in the suppression of human spermatogenesis when used alone. We found that a testosterone implant dose of 800 mg (four 200-mg implants), releasing 6 mg testosterone/day, when administered alone achieves inadequate suppression of spermatogenesis for a hormonal male contraceptive. A still lower dose (2 200-mg implants, 3 mg testosterone/day) has mg testosterone buciclate, a novel testosterone ester containing 760 mg testosterone, which produced azoospermia in 3 of 8 healthy men, but minimal spermatogenic suppression in the remaining volunteers (7). Given the prolonged zero order testosterone release by testosterone buciclate injection (5, 7) and extrapolating our previous findings, it can be expected that higher testosterone buciclate doses would improve spermatogenic suppression, but still not provide uniform azoospermia.
Although our findings may be reliably extrapolated to other true testosterone depots (such as testosterone microspheres), they may not apply to synthetic androgens, particularly those metabolically different from testosterone by virtue of restricted activation by aromatization and/or 5cY-reduction (18). Extrusions of a single implant were observed in only 2 men among 30 participants in this study, a rate consistent with that of pellet extrusions among hypogonadal men (5-7%) (Handelsman, D. J., unpublished observations). As these 2 men became azoospermic and had no evidence of androgen deficiency, it is unlikely that these extrusions materially affected our findings. This study is the first demonstration of synergism between a depot progestin and a depot androgen in suppressing human spermatogenesis.
We observed markedly greater suppression of sperm output by the addition of a depot progestin to a depot androgen. The absence of significant clinical or biochemical adverse effects or discontinuations during this study confirm and extend our previous observations with a higher dose (1200 mg, 9 mg/day) of testosterone implants. These findings illustrate the advantage of using the minimum testosterone doses that still maintain adequate androgen replacement. Based on our experience with hypogonadal men, this would be 800 mg testosterone (6 mg/ day), which closely replicates the normal endogenous testosterone production rate. Although such doses provide inadequate suppression of spermatogenesis when used alone, they would provide adequate androgen replacement if another gonadotropin-suppressing agent, such as a progestin or GnRH antagonist, was used concurrently. Further lowering of testosterone doses would provide inadequate androgen replacement, with likely adverse consequences for structure and function of bone, muscle, and other androgen-dependent tissues, including loss of libido. In deciding the relative advantages of androgen alone vs. androgen combinations with a second agent, the key issue is the relative safety of reducing testosterone exposure from 9 to 6 mg/ day us. the addition of a second gonadotropinsuppressing agent, and the optimal approach remains to be determined (see discussion in Ref 10).
This path-finding study was not designed to resolve the issue of the long term risks and benefits of androgen usage. These considerations will require evaluation of the risks of cardiovascular or prostate disease balanced against the noncontraceptive benefits on bone, muscle, and general anabolic effects during prolonged surveillance over decades, as has been required for female hormonal contraception. Nevertheless, the short term findings in this study are reassuring. The only relevant established cardiovascular risk association in men is that lowered blood testosterone levels are associated with excess cardiovascular risk (30). The absence of lipid changes together with the dose-sparing effect of a steady state depot formulation and maintenance of completely physiological testosterone concentrations throughout the study indicate that testosterone-based male contraceptive regimens with minimal metabolic impact on biochemical variables can be developed. Further study of the influence of physiological doses of androgens and progestins on nonlipid cardiovascular risk factors, such as vascular reactivity (31, 32), also need evaluation. Similarly, the unchanging prostatespecific antigen concentrations are evidence against any change in total prostate size under the conditions pertaining to this study. This supports the strategy that maintaining adequate physiological testosterone concentrations and avoiding excessive or underreplacement dosages may minimize long term cardiovascular or prostate risk from androgen-based hormonal regimens for male contraception.
The present study demonstrates the feasibility and advantages of using a depot progestin/ androgen combination for hormonal male contraception. The ongoing public interest and enthusiastic participation in such contraceptive studies signal the motivation and willingness of men to continue to share the burdens as well as the benefits of reliable contraception. If more convenient depot formulations can be made available, the promise of hormonal contraception for men indicated by the WHO studies and the clear community niche for hormonal male methods can be brought into fruitful conjunction.
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